Tianjin Zhong Xin Pharma

Tianjin Zhong Xin Pharma: expects to report about 70 - 90% yoy rise in net profit for FY12 due to gain on disposal of subsidiary, increase in the return on invmt and increase in operating profits from the group's main business. The stock gapped up this morning, minting a fresh 52 wk high. Last done at US$0.81, +6.6%.